Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)

China · Delayed Price · Currency is CNY

5.46

+0.05 (0.92%)

Sep 10, 2026, 3:04 PM CST

SHE:002581 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Revenue	298.07	274.81	360.41	429.79	357.08	402.71
Revenue Growth	35.24%	-23.75%	-16.14%	20.36%	-11.33%	45.47%
Gross Profit	86.38	121.89	272.74	336.5	280.44	316.88
Operating Income	-183.45	-189.51	-90.86	-155.81	-175.57	-203.95
Net Income	-144.45	-116.28	-137.31	-332.46	-14.68	271
Earnings Per Share	-0.22	-0.18	-0.21	-0.50	-0.02	0.41
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Biopharmaceutical	188.68	360.41
Traditional Chinese Medicine Decoction Pieces Processing	83.07	-
Pharmaceutical Distribution	2.99	-
Unallocated Other	0.07	-
Total	274.81	360.41

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Investments	242.84	220.27	506.4	151.91	183.8	187.8
Total Debt	58.15	61.43	2.94	14.55	165.35	177.16
Net Cash (Debt)	184.68	158.84	503.47	137.36	18.45	10.64
Net Cash Growth	-59.15%	-68.45%	266.52%	644.38%	73.50%	-90.91%
Net Cash Per Share	0.28	0.24	0.76	0.21	0.03	0.02

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Cash Flow	-180.87	-253.73	-6.55	-36.51	-54.49	-46.02
Capital Expenditures	-166.45	-179.7	-9.01	-4.32	-31.46	-60.85
Free Cash Flow	-347.31	-433.43	-15.56	-40.82	-85.95	-106.86
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Gross Margin	28.98%	44.36%	75.67%	78.30%	78.54%	78.69%
Operating Margin	-61.55%	-68.96%	-25.21%	-36.25%	-49.17%	-50.64%
Pretax Margin	-62.21%	-63.87%	-40.56%	-72.88%	3.56%	69.18%
Profit Margin	-48.46%	-42.31%	-38.10%	-77.35%	-4.11%	67.29%
FCF Margin	-116.52%	-157.72%	-4.32%	-9.50%	-24.07%	-26.53%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
PE Ratio	-	-	-	-	-	51.98
PS Ratio	11.97	18.01	19.48	22.41	29.10	34.98